slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
224,851-224,880 of 319,975
12
Neon-style typography on a dark blue background.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations 1 hit
13
BenevolentAI | Investor Conference Presentation Deck | 22 slidesBenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations 1 hit
14
Slide includes both corporate facts and leadership headshots.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations 1 hit
15
BenevolentAI | Investor Conference Presentation Deck | 22 slidesBenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations 1 hit
16
Uses a combination of two pillars (Tech and Science) leading to a unified USP.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Loop · Golden Circle1 hit
17
The slide uses a Gantt-style visualization to show the status of various drug development programs.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Loop · Golden Circle1 hit
18
The slide uses a process-like visual to represent the three parts of the study.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations 1 hit
19
Includes biographical context on the founder of 9xchange.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations 1 hit
20
The table presents normalized operating loss and EPS, excluding specific exceptional items as detailed in the footnotes.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Financials1 hit
21
The table reconciles reported operating loss to normalised operating loss by adding back non-recurring restructuring and transaction-related costs.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Financials1 hit
22
The slide provides a bridge between operating loss and cash flow, with explanatory notes on the right.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Financials1 hit
01
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
02
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
03
The slide uses a linked-circle diagram to represent the company's core pillars.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
04
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
05
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
06
The slide uses a visual comparison between healthy cells (alkaline) and cancer cells (acidic) to illustrate the binding mechanism.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a three-column layout to compare different therapeutic modalities enabled by the same platform technology.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
08
The chart uses a Gantt-style visualization to show the progress of drug candidates through clinical phases.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
09
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
10
The slide uses a visual comparison framework to illustrate the mechanism of action (MOA) of the drug candidate.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
11
The chart uses a dot plot format to show the occurrence of specific GI symptoms over a 29-day study period across different subjects.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
12
The diagram illustrates a dose escalation study design with combination therapy.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
13
Data cut date: 15Nov23BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
Data cut date: 15Nov23. Pt = Platinum.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
Data table showing safety profile by dose cohort.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
The slide highlights a low incidence of immune-related adverse events (2 out of 18 patients).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
This is a classic 'spider plot' or 'swimmer plot' variant used in oncology clinical trials to visualize individual patient tumor burden changes over time.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The chart is a spider plot (or swimmer plot variant) showing change in target lesion size over time for individual patients.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
Before-after medical imaging comparison.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit